Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.

Published Date: 01 Sep 2023

A recent study found an association between the treatment for chronic myeloid leukemia (CML) with nilotinib (a tyrosine kinase inhibitor).

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Interleukin-6 may boost prediction of obesity-related cancers

2.

A researcher has found that yoga exhibits the "most improvement" in helping long-term cancer survivors restore their brain health.

3.

Could AI plus lasers help catch very early breast cancers?

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

Patients with chronic myeloid leukemia who take nilotinib are at higher risk for diabetes and hyperlipidemia.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot